Reckitt Benckiser to pay $1.4bn over opioid treatment sales

Reckitt Benckiser has agreed to pay a $1.4 billion fine to settle a US investigation into the sales and marketing of opioid addiction treatment Suboxone film (buprenorphine and naloxone) by its former prescriptions business.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Indivior to launch generic after SCOTUS refuses petition

22 February 2019 Indivior has launched a generic version of its opioid addiction drug Suboxone (buprenorphine and naloxone) Film, one day after the US Supreme Court denied its request to put a lower court’s ruling on hold.

Americas

Fed Circuit refusal paves way for Suboxone generics

5 February 2019 Rivals of British pharmaceutical company Indivior will soon be able to sell generic versions of opioid addiction treatment Suboxone film following a ruling of the US Court of Appeals for the Federal Circuit.

More features

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation: Follow the money (Part I)

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

Former PTAB judge joins Sterne Kessler

Reckitt Benckiser to pay $1.4bn over opioid treatment sales

More on this story

Editor's picks

Editor's picks

More features